Details for Patent: 9,283,209

Which drugs does patent 9,283,209 protect, and when does it expire?

Patent 9,283,209 protects JADENU and is included in one NDA.

This patent has sixty-seven patent family members in forty-two countries.

Summary for Patent: 9,283,209

Title:	Oral formulations of deferasirox
Abstract:	Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
Inventor(s):	Ghosh; Indrajit (Hillsborough, NJ), Zhang; Jia-Ai (Skillman, NJ)
Assignee:	NOVARTIS AG (Basel, CH)
Application Number:	14/198,872
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,283,209
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 9,283,209

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No			Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No			Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,283,209

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095058
Australia	2014224198
Australia	2017203897
Brazil	112015021254
Canada	2890465
Chile	2015002495